Nature's toolbox against tau aggregation: An updated review of current research

Ageing Research Reviews
2023.0

Abstract

Tau aggregation is a hallmark of several neurodegenerative disorders, such as Alzheimer's disease (AD), frontotemporal dementia, and progressive supranuclear palsy. Hyperphosphorylated tau is believed to contribute to the degeneration of neurons and the development of these complex diseases. Therefore, one potential treatment for these illnesses is to prevent or counteract tau aggregation. In recent years, interest has been increasing in developing nature-derived tau aggregation inhibitors as a potential treatment for neurodegenerative disorders. Researchers have become increasingly interested in natural compounds with multifunctional features, such as flavonoids, alkaloids, resveratrol, and curcumin, since these molecules can interact simultaneously with the various targets of AD. Recent studies have demonstrated that several natural compounds can inhibit tau aggregation and promote the disassembly of pre-formed tau aggregates. Nature-derived tau aggregation inhibitors hold promise as a potential treatment for neurodegenerative disorders. However, it is important to note that more research is needed to fully understand the mechanisms by which these compounds exert their effects, safety and efficacy in preclinical and clinical studies. Nature-derived inhibitors of tau aggregation are a promising new direction in the research of neurodegenerative complexities. This review focuses on the natural products that have proven to be a rich supply for inhibitors in tau aggregation and their uses in neurodegenerative complexities, including AD.

Knowledge Graph

Similar Paper

Nature's toolbox against tau aggregation: An updated review of current research
Ageing Research Reviews 2023.0
Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease
Journal of Medicinal Chemistry 2013.0
Alzheimer’s Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration
Current Molecular Pharmacology 2022.0
Usnic acid derivatives as tau-aggregation and neuroinflammation inhibitors
European Journal of Medicinal Chemistry 2020.0
The Diarylheptanoid (+)-a<i>R</i>,11<i>S-</i>Myricanol and Two Flavones from Bayberry (<i>Myrica cerifera</i>) Destabilize the Microtubule-Associated Protein Tau
Journal of Natural Products 2011.0
Synthesis and evaluation of 1,2,3,4-tetrahydro-1-acridone analogues as potential dual inhibitors for amyloid-beta and tau aggregation
Bioorganic &amp; Medicinal Chemistry 2018.0
Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors
Journal of Medicinal Chemistry 2018.0
Possible neuroprotective effects of amide alkaloids from Bassia indica and Agathophora alopecuroides: in vitro and in silico investigations
RSC Advances 2022.0
Multi-target Natural and Nature-Inspired Compounds against Neurodegeneration: A Focus on Dual Cholinesterase and Phosphodiesterase Inhibitors
Applied Sciences 2021.0
Repurposing nitrocatechols: 5-Nitro-α-cyanocarboxamide derivatives of caffeic acid and caffeic acid phenethyl ester effectively inhibit aggregation of tau-derived hexapeptide AcPHF6
European Journal of Medicinal Chemistry 2019.0